3 active not recruiting, 3 completed, 3 recruiting, 2 unknown. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 3, Completed 3, Recruiting 3, Unknown 2, Not yet recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Neuroendocrine Neoplasm: new trials by email Literature Review of Neuroendocrine Neoplasm trials Research Report on Neuroendocrine Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms CTX-471 - Neuroendocrine Neoplasm, Neuroendocrine Carcinomas | Phase 2 | Not yet recruiting | Compass Therapeutics | 58 | 2026-09-01 | 2026-07-06 |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors CRN09682 - SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors | Phase 1 / Phase 2 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-11-26 | 2026-10-13 |
| Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial Somatostatin analog - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1 | Phase 2 / Phase 3 | Recruiting | The Netherlands Cancer Institute | 39 | 2024-06-25 | 2025-03-03 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With NEN PM8002, FOLFIRI - Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | Biotheus Inc. | 31 | 2023-05-17 | 2026-07-09 |
| Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) Sintilimab, IBI310, Surufatinib - Neuroendocrine Neoplasm | Phase 2 | Recruiting | Peking University | 30 | 2022-07-12 | 2025-03-14 |
| Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Chidamide, Sintilimab - Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3 | Phase 2 | Unknown | Peking Union Medical College Hospital | 23 | 2021-11-17 | 2021-11-24 |
| Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients Lu-177-DOTA-Octreotide - Neuroendocrine Neoplasm | Phase 2 | Recruiting | Tine Gregersen, MD | 100 | 2020-02-01 | 2024-12-09 |
| Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Nivolumab, Carboplatin, Etoposide - Neuroendocrine Tumors, Neuroendocrine Neoplasm | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 37 | 2019-10-11 | 2025-01-13 |
| Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Everolimus, Lenvatinib - Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 36 | 2019-07-30 | 2026-09-18 |
| Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate - Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm | Phase 2 | Completed | Nicholas Fidelman, MD | 32 | 2018-08-27 | 2026-08-28 |
| A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms 18F-AlF-NOTA-octreotide, PET/CT - Neuroendocrine Neoplasm | Phase 1 / Phase 2 | Unknown | Xiangya Hospital of Central South University | 65 | 2018-01-02 | 2018-04-30 |
| Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study - Carcinoid Tumor, Metastatic Carcinoid Tumor | Phase 2 | Completed | Roswell Park Cancer Institute | 32 | 2015-05-15 | 2023-12-26 |
Neuroendocrine Tumors (12) · Carcinoma, Neuroendocrine (3) · Carcinoid Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasm Metastasis (1)
Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Adenocarcinoma (4) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms by Site (1) · Neoplasms, Multiple Primary (1)
lutetium Lu 177 dotatate (2) · sintilimab (2) · Al18F-NOTA-octreotide (1) · Carboplatin (1) · Etoposide (1) · Everolimus (1) · IFL protocol (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Nivolumab (1) · Positron Emission Tomography Computed Tomography (1) · Somatostatin (1) · lenvatinib (1) · nintedanib (1) · pembrolizumab (1) · surufatinib (1)
Biotheus Inc. (1) · Compass Therapeutics (1) · Crinetics Pharmaceuticals Inc. (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · M.D. Anderson Cancer Center (1) · Nicholas Fidelman, MD (1) · Peking Union Medical College Hospital (1) · Peking University (1) · Roswell Park Cancer Institute (1) · The Netherlands Cancer Institute (1) · Tine Gregersen, MD (1) · Xiangya Hospital of Central South University (1)
China (4) · United States (4) · Spain (2) · Denmark (1) · Netherlands (1)
Chunmei Bai, M.D. (1) · Jianming Xu (1) · Nageshwara V Dasari (1) · Nicholas Fidelman, MD (1) · Renuka Iyer (1) · Tingting Long, MD,Phd (1)